Phase 3 Clinical Trial of Dimebon in Alzheimer’s Disease (The CONNECTION Study)

We are enrolling patients in the CONNECTION study, a second pivotal Phase 3 trial of Dimebon in patients with mild-to-moderate Alzheimer’s disease. Study highlights:

• International, double-blind, placebo-controlled safety and efficacy study
• Designed to confirm the positive findings of the first pivotal 12-month safety and efficacy study of Dimebon, which showed statistically significant improvements over placebo in memory, thinking, activities of daily living, behavior, and overall function
• Enrolling 525 patients at sites in the United States, Europe and South America
• Patients aged 50 and older with a clinical diagnosis of Alzheimer’s disease, who are not taking any other Alzheimer’s prescription medicines, may be eligible to participate
• Two-thirds of patients will receive Dimebon and one-third will receive placebo
• After six months of treatment, all patients—including those receiving placebo—will be given the opportunity to receive Dimebon until marketing authorization

For more information on CONNECTION study locations, eligibility and enrollment, please visit www.connectionstudy.com or call toll-free 1-877-888-6386.

Phase 2 Study of Dimebon in Huntington’s Disease

In July 2008, we announced positive safety and efficacy results from our Phase 2 trial of Dimebon for the treatment of Huntington’s disease, which was conducted in collaboration with the Huntington Study Group, a network of clinical trial investigators from academic and research institutions throughout the United States, Canada, Europe and Australia.

We plan to continue further development of Dimebon in patients with mild-to-moderate Huntington’s disease based on the positive results seen in this Phase 2 trial.